Avobis Bio Announces Expanded Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial to be Presented at European Crohn's and Colitis Organisation (ECCO) Congress
PR Newswire —
- Outcomes in new cohort are favorable and consistent to previously reported randomized cohort for Crohn's Perianal Fistulas - NEWARK, Del., Jan. 29, 2026 /PRNewswire/ -- Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced that expanded primary...